Literature DB >> 21840723

The structure-activity relationship of urea derivatives as anti-tuberculosis agents.

Joshua R Brown1, Elton J North, Julian G Hurdle, Christophe Morisseau, Jerrod S Scarborough, Dianqing Sun, Jana Korduláková, Michael S Scherman, Victoria Jones, Anna Grzegorzewicz, Rebecca M Crew, Mary Jackson, Michael R McNeil, Richard E Lee.   

Abstract

The treatment of tuberculosis is becoming more difficult due to the ever increasing prevalence of drug resistance. Thus, it is imperative that novel anti-tuberculosis agents, with unique mechanisms of action, be discovered and developed. The direct anti-tubercular testing of a small compound library led to discovery of adamantyl urea hit compound 1. In this study, the hit was followed up through the synthesis of an optimization library. This library was generated by systematically replacing each section of the molecule with a similar moiety until a clear structure-activity relationship was obtained with respect to anti-tubercular activity. The best compounds in this series contained a 1-adamantyl-3-phenyl urea core and had potent activity against Mycobacterium tuberculosis plus an acceptable therapeutic index. It was noted that the compounds identified and the pharmacophore developed is consistent with inhibitors of epoxide hydrolase family of enzymes. Consequently, the compounds were tested for inhibition of representative epoxide hydrolases: M. tuberculosis EphB and EphE; and human soluble epoxide hydrolase. Many of the optimized inhibitors showed both potent EphB and EphE inhibition suggesting the antitubercular activity is through inhibition of multiple epoxide hydrolase enzymes. The inhibitors also showed potent inhibition of humans soluble epoxide hydrolase, but limited cytotoxicity suggesting that future studies must be towards increasing the selectivity of epoxide hydrolase inhibition towards the M. tuberculosis enzymes.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840723      PMCID: PMC3176295          DOI: 10.1016/j.bmc.2011.07.034

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

1.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors:  Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

Review 2.  Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles.

Authors:  Christophe Morisseau; Bruce D Hammock
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

Review 3.  Multi-targeting by monotherapeutic antibacterials.

Authors:  Lynn L Silver
Journal:  Nat Rev Drug Discov       Date:  2007-01       Impact factor: 84.694

4.  Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies.

Authors:  Paul D Jones; Nicola M Wolf; Christophe Morisseau; Paul Whetstone; Bertold Hock; Bruce D Hammock
Journal:  Anal Biochem       Date:  2005-08-01       Impact factor: 3.365

5.  Cloning, expression, purification, crystallization and preliminary X-ray studies of epoxide hydrolases A and B from Mycobacterium tuberculosis.

Authors:  Bichitra K Biswal; Grace Garen; Maia M Cherney; Craig Garen; Michael N G James
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-01-27

6.  Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates.

Authors:  Richard E Lee; Marina Protopopova; Emma Crooks; Richard A Slayden; Marianne Terrot; Clifton E Barry
Journal:  J Comb Chem       Date:  2003 Mar-Apr

7.  Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.

Authors:  Marina Protopopova; Colleen Hanrahan; Boris Nikonenko; Rowena Samala; Ping Chen; Jackie Gearhart; Leo Einck; Carol A Nacy
Journal:  J Antimicrob Chemother       Date:  2005-09-19       Impact factor: 5.790

8.  cDNA cloning and expression of a soluble epoxide hydrolase from human liver.

Authors:  J K Beetham; T Tian; B D Hammock
Journal:  Arch Biochem Biophys       Date:  1993-08-15       Impact factor: 4.013

9.  Potent urea and carbamate inhibitors of soluble epoxide hydrolases.

Authors:  C Morisseau; M H Goodrow; D Dowdy; J Zheng; J F Greene; J R Sanborn; B D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

10.  Identification of novel diphenyl urea inhibitors of Mt-GuaB2 active against Mycobacterium tuberculosis.

Authors:  Veeraraghavan Usha; Sudagar S Gurcha; Andrew L Lovering; Adrian J Lloyd; Athina Papaemmanouil; Robert C Reynolds; Gurdyal S Besra
Journal:  Microbiology (Reading)       Date:  2010-11-16       Impact factor: 2.777

View more
  33 in total

1.  Copper complexation screen reveals compounds with potent antibiotic properties against methicillin-resistant Staphylococcus aureus.

Authors:  Mehri Haeili; Casey Moore; Christopher J C Davis; James B Cochran; Santosh Shah; Tej B Shrestha; Yaofang Zhang; Stefan H Bossmann; William H Benjamin; Olaf Kutsch; Frank Wolschendorf
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 2.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

3.  Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.

Authors:  Sandra Codony; Elena Valverde; Rosana Leiva; José Brea; M Isabel Loza; Christophe Morisseau; Bruce D Hammock; Santiago Vázquez
Journal:  Bioorg Med Chem       Date:  2019-08-26       Impact factor: 3.641

Review 4.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

Authors:  Daniel T Hoagland; Jiuyu Liu; Robin B Lee; Richard E Lee
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

5.  Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity.

Authors:  Nicholas D Franz; Juan Manuel Belardinelli; Michael A Kaminski; Louis C Dunn; Vinicius Calado Nogueira de Moura; Michael A Blaha; Dan D Truong; Wei Li; Mary Jackson; E Jeffrey North
Journal:  Bioorg Med Chem       Date:  2017-05-08       Impact factor: 3.641

6.  Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties.

Authors:  E Jeffrey North; Michael S Scherman; David F Bruhn; Jerrod S Scarborough; Marcus M Maddox; Victoria Jones; Anna Grzegorzewicz; Lei Yang; Tamara Hess; Christophe Morisseau; Mary Jackson; Michael R McNeil; Richard E Lee
Journal:  Bioorg Med Chem       Date:  2013-02-26       Impact factor: 3.641

7.  A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone.

Authors:  Anna E Grzegorzewicz; Jana Korduláková; Victoria Jones; Sarah E M Born; Juan M Belardinelli; Adrien Vaquié; Vijay A K B Gundi; Jan Madacki; Nawel Slama; Françoise Laval; Julien Vaubourgeix; Rebecca M Crew; Brigitte Gicquel; Mamadou Daffé; Hector R Morbidoni; Patrick J Brennan; Annaik Quémard; Michael R McNeil; Mary Jackson
Journal:  J Biol Chem       Date:  2012-09-21       Impact factor: 5.157

8.  Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target.

Authors:  Cedric P Owens; Nicholas Chim; Celia W Goulding
Journal:  Future Med Chem       Date:  2013-08       Impact factor: 3.808

9.  Antiinfectives targeting enzymes and the proton motive force.

Authors:  Xinxin Feng; Wei Zhu; Lici A Schurig-Briccio; Steffen Lindert; Carolyn Shoen; Reese Hitchings; Jikun Li; Yang Wang; Noman Baig; Tianhui Zhou; Boo Kyung Kim; Dean C Crick; Michael Cynamon; J Andrew McCammon; Robert B Gennis; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

10.  Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.

Authors:  Wei Li; Andrés Obregón-Henao; Joshua B Wallach; E Jeffrey North; Richard E Lee; Mercedes Gonzalez-Juarrero; Dirk Schnappinger; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.